These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3918971)

  • 1. Phase I and pharmacologic study of oral ftorafur and X ray therapy in advanced gastrointestinal cancer.
    Byfield JE; Sharp TR; Hornbeck CL; Frankel SS; Floyd RA; Griffiths JC
    Int J Radiat Oncol Biol Phys; 1985 Mar; 11(3):597-602. PubMed ID: 3918971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug.
    Byfield JE; Hornbeck CL; Frankel SS; Sharp TR; Griffiths JC
    Cancer Treat Rep; 1985 Jun; 69(6):645-52. PubMed ID: 3926308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of 5-FU, ftorafur, and a major serum metabolite following ftorafur chemotherapy.
    Hornbeck CL; Griffiths JC; Floyd RA; Ginther NC; Byfield JE; Sharp TR
    Cancer Treat Rep; 1981; 65(1-2):69-72. PubMed ID: 6784923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma.
    Queisser W; Schnitzler G; Schaefer J; Arnold H; Drings P; Fritze D; Geldmacher J; Hartwich G; Herrmann R; Kempf P; König H; Meiser RJ; Nedden R; von Oldershausen HF; Pappas A; Sievers H; Wahrendorf J; Westerhausen M; Witte S
    Recent Results Cancer Res; 1981; 79():82-92. PubMed ID: 6795701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
    Ho DH; Covington W; Brown N; Lin SN; Pazdur R; Huo YY; Creaven PJ; Rustum YM; Meropol NJ; Lassere Y; Kuritani J; Hayakawa T
    Cancer Chemother Pharmacol; 2000; 46(5):351-6. PubMed ID: 11127938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of 72-hour infused 5-fluorouracil and hyperfractionated cyclical radiation.
    Byfield JE; Frankel SS; Sharp TR; Hornbeck CL; Callipari FB
    Int J Radiat Oncol Biol Phys; 1985 Apr; 11(4):791-800. PubMed ID: 3980274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
    Valdivieso M; Bodey GP; Gottlieb JA; Freireich EJ
    Cancer Res; 1976 May; 36(5):1821-4. PubMed ID: 1268838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II studies of oral tegafur (ftorafur).
    Ansfield FJ; Kallas GJ; Singson JP
    J Clin Oncol; 1983 Feb; 1(2):107-10. PubMed ID: 6422005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
    Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
    Meropol NJ; Rustum YM; Petrelli NJ; Rodriguez-Bigas M; Frank C; Ho DH; Kurowski M; Creaven PJ
    Cancer Chemother Pharmacol; 1996; 37(6):581-6. PubMed ID: 8612313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of oral tegafur.
    Bedikian AY; Bodey GP; Valdivieso M; Burgess MA
    Cancer Treat Rep; 1983 Jan; 67(1):81-4. PubMed ID: 6413058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of combined oral uracil and ftorafur.
    Ho DH; Covington WP; Pazdur R; Brown NS; Kuritani J; Newman RA; Raber MN; Krakoff IH
    Drug Metab Dispos; 1992; 20(6):936-40. PubMed ID: 1362949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
    J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
    Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
    J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 5-fluorouracil and ftorafur. I. Quantitative and qualitative differences in toxicity to mice.
    Johnson RK; Garibjanian BT; Houchens DP; Kline I; Gaston MR; Syrkin AB; Goldin A
    Cancer Treat Rep; 1976 Sep; 60(9):1335-45. PubMed ID: 797449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
    Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
    Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.